Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 12/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | BAD | Q92934 | 10/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 9/20 | 0.40 |
| ▸ | BCL2 | P10415 | 5/20 | 0.40 |
| ▸ | PMAIP1 | Q13794 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19635405 | 0.94 | MCL1 (0.43) | MCL1ALBBADBCL2L1BCL2 | |
| SCHEMBL19615535 | 0.94 | MCL1 (0.47) | MCL1ALBBADBCL2L1BCL2 | |
| SCHEMBL19635262 | 0.93 | MCL1 (0.49) | MCL1ALBBADBCL2L1BCL2 | |
| SCHEMBL22436834 | 0.92 | BAD (0.47) | MCL1ALBBADBCL2L1BCL2 | |
| SCHEMBL19635636 | 0.91 | MCL1 (0.42) | MCL1ALBBADBCL2L1BCL2 | |
| SCHEMBL19616065 | 0.91 | MCL1 (0.48) | MCL1ALBBADBCL2L1BCL2 | |
| SCHEMBL19615861 | 0.88 | MCL1 (0.47) | MCL1ALBBADBCL2L1BCL2 | |
| SCHEMBL19635521 | 0.88 | MCL1 (0.43) | MCL1ALBBADBCL2L1BCL2 | |
| SCHEMBL19615921 | 0.88 | MCL1 (0.55) | MCL1ALBBADBCL2L1BCL2 | |
| SCHEMBL28637851 | 0.88 | MCL1 (0.54) | MCL1ALBBADBCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| CN-109715632-B | Macrocyclic indole derivatives | 拜尔公开股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | MCL1 62/4885ALB 2042/4885BAD 358/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | MCL1 56/4885ALB 3051/4885BAD 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.